In connection with the reduction in workforce, Bellerophon Therapeutics, Inc. intends to enter into separation and/or transition agreements with each of Peter Fernandes, the Companyâs Chief Executive Officer, which are expected to provide for their separation of employment, effective July 15, 2023 or any such later date as agreed upon by the Company and such individual.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0567 USD | +0.71% | +0.89% | +53.24% |
May. 02 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 25 | North American Morning Briefing : More Tech -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+53.24% | 689K | |
+7.73% | 113B | |
+10.62% | 106B | |
+0.41% | 22.27B | |
-12.09% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-4.89% | 17.24B | |
+6.71% | 14.29B | |
+36.06% | 12.52B |
- Stock Market
- Equities
- BLPH Stock
- News Bellerophon Therapeutics, Inc.
- Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023